MedTrace Logo

The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders

NCT02357472 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-24

Study results available
· View outcomes & findings →

Summary

The supplementation of Dehydroepiandrosterone (DHEA) has been used in some centers for patients with previous poor ovarian reserve and response in an attempt to improve pregnancy outcomes. However, there still has controversy on the clinical effect on the 75mg/d for the use,especially in Asian people. Whether the double dosage of DHEA in patients with poor ovarian reserve and response in China can improve the IVF outcome with little side effect is unknown.

The aim of this randomized controlled study is to compare the effect of a higher dose (150mg daily) and a standard dose (75mg daily) of DHEA on the number of oocytes obtained in poor ovarian responders. The effect of DHEA action on the cumulus cells will be examined.

Conditions

Interventions

DIETARY_SUPPLEMENT

dehydroepiandrosterone

high dose group treatment represent for 50mg t.i.d. Patients in these group will take one capsule each time and three times a day for three months before entering into IVF cycles.

Sponsors & Collaborators

  • ShangHai Ji Ai Genetics & IVF Institute

    lead OTHER

Principal Investigators

  • Xiao Xi Sun, PHD,MD · Shang Hai JIAi genetics & IVF center

  • Jing Fu, MD · Shang Hai JIAi genetics & IVF center

  • Ying Su Liu, PHD,MD · Shang Hai JIAi Genetics & IVF center

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2014-12-31
Completion
2015-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02357472 on ClinicalTrials.gov